QGC-001

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529017

CAS#: 648927-86-0

Description: QGC-001, also known as RB-150 or Firibastat, is a glutamyl aminopeptidase antagonist potentially for the treatment of hypertension.


Price and Availability

Size
Price

Size
Price

Size
Price

QGC-001 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 529017
Name: QGC-001
CAS#: 648927-86-0
Chemical Formula: C8H20N2O6S4
Exact Mass: 368.0204
Molecular Weight: 368.49
Elemental Analysis: C, 26.08; H, 5.47; N, 7.60; O, 26.05; S, 34.80


Synonym: RB-150; QGC-001; RB150; QGC001; RB 150; QGC 001; Firibastat

IUPAC/Chemical Name: (S)-3-amino-4-(((S)-2-amino-4-sulfobutyl)disulfaneyl)butane-1-sulfonic acid

InChi Key: HJPXZXVKLGEMGP-YUMQZZPRSA-N

InChi Code: InChI=1S/C8H20N2O6S4/c9-7(1-3-19(11,12)13)5-17-18-6-8(10)2-4-20(14,15)16/h7-8H,1-6,9-10H2,(H,11,12,13)(H,14,15,16)/t7-,8-/m0/s1

SMILES Code: O=S(CC[C@H](N)CSSC[C@@H](N)CCS(=O)(O)=O)(O)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Balavoine F, Azizi M, Bergerot D, De Mota N, Patouret R, Roques BP,
Llorens-Cortes C. Randomised, double-blind, placebo-controlled, dose-escalating
phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug.
Clin Pharmacokinet. 2014 Apr;53(4):385-95. doi: 10.1007/s40262-013-0125-y. PubMed
PMID: 24337978.